Replies to post #110579 on Amarantus Bioscience Holdings Inc (AMBS)

[GS1]

Financing company would not give any better rates to Gerald as company is not producing any revenues so interest rates will be higher if financing is approved. This is true across the board for any startup company.

Gerald has another option of not paying interest and involve financiers that would dilute heck out of it. So which option is suitable.

Gerald is trying to make best out of situation that currently presents. Even though I'm not big supporter of these terms this is probably the best out of rest available. This gives Gerald time to pay bills as well time to grow other business such as Lympro that will bring in revenue.

By using series E 12%, Gerald is basically paying 12% interest on draw down amount. i.e if draw down is 4 million then about 450K interest has to be paid per quarter. In order to pay 450K interest he has to dilute 8 million shares per quarter @.08 pps. Not bad at all if you ask me.

Just my 2 cents....

[breezy1]

How about a share dividend 10%
To all share holder of record dec 31


Give the real owners a gift

[JPetroInc]

sad but true...AMBS credit lines are haevily leveraged - and the already heavily papered runway has just been extended a 2nd 1-Bil. AS. The street has difficulty taking a stake in this security below $0.10 and one that has an imminent RS just around the corner.

You can not build "shareholder value" and "share appreciation" while diluting millions of shares monthly onto the backs of your loyal 'long term' shareholders - it simply doesn't work. Gerald intuitively knows this - but won't publicly admit it.

Bring in an award winning revenue contract on LymPro, or better yet, acquire a cash flow positive security that is already trading on the NAS, and one that would back up all the talk of "financial engineering"